Aktienanalyse zu Park Ha Biological Technology Co Ltd (BYAH)BYAHPark Ha Biological Technology Co Ltd

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market. It operates in the Consumer Non-Cyclicals sector.

Park Ha Biological Technology Co Ltd (BYAH) appears to be a good buy right now due to its recent price increase of 20% to $1.77 in pre-market trading, reflecting a positive sentiment in the biotech sector. Additionally, the company secured $2 million in a direct offering, which indicates strong market confidence and a strategic intent to expand its business. However, the stock has a high forward P/E of 0 and a negative P/E ratio of -5.93, which suggests that while there is potential for growth, there are also risks associated with its current valuation.